Multiple Sclerosis (MS) Drug Market

RECENT NEWS
Benzinga  May 21  Comment 
Today Biogen Idec (NASDAQ: BIIB) announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of PLEGRIDY™ (peginterferon beta-1a), the company's pegylated ...
FierceBiotech  May 20  Comment 
Shares of XenoPort skidded lower this morning after the biotech announced its lead experimental drug had decisively failed a late-stage study for spasticity triggered by multiple sclerosis. The troubled biopharma company, which has been struggling...
Benzinga  May 20  Comment 
XenoPort (Nasdaq: XNPT) announced today top-line results from its pivotal Phase 3 clinical trial of arbaclofen placarbil (AP) for the treatment of patients with spasticity due to multiple sclerosis (MS). The trial was unsuccessful in demonstrating...
MedPage Today  May 6  Comment 
(MedPage Today) -- Multiple sclerosis is more common in blacks than previously thought, especially among women, a population-based study showed.
MedPage Today  Apr 25  Comment 
(MedPage Today) -- Patients with clinically isolated syndrome were significantly less likely to progress to definite multiple sclerosis after receiving the oral drug teriflunomide (Aubagio), its manufacturer said.
MedPage Today  Apr 23  Comment 
(MedPage Today) -- Progression from clinically isolated syndrome to definite multiple sclerosis was significantly associated with atrophy in the thalamus among patients treated with interferon-beta-1a, researchers said.
MedPage Today  Apr 20  Comment 
(MedPage Today) -- Several new medications for multiple sclerosis are in the short-term pipeline, and other treatments, including cell therapies, are on the more distant horizon, according to a well-known MS researcher.
Forbes  Apr 15  Comment 
Ampyra, a pill approved to help patients with multiple sclerosis walk, has put Acorda Therapeutics in the small club of profitable biotechnology companies. The drug generated $266 million in annual sales last year, helping Acorda generate a net...
MedPage Today  Apr 11  Comment 
(MedPage Today) -- Fetal defects in thymic function and inadequate circulating levels of vitamin D may explain the well recognized influence of birth month on risk for multiple sclerosis, British researchers suggested.
Benzinga  Apr 10  Comment 
Omeros Corporation (NASDAQ: OMER) today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds...




 
TOP CONTRIBUTORS

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki